Results 181 to 190 of about 2,678,588 (368)

Symptom cluster profiles in adolescents with inflammatory bowel disease: Cross‐sectional study using ImproveCareNow data

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Sleep disturbance, pain, anxiety, depression, and fatigue are prevalent in adolescents and young adults with inflammatory bowel disease (IBD). These symptoms often present in co‐occurring sets, known as symptom clusters. We aimed to identify distinct symptom clusters and factors associated with symptom profiles in adolescents with ...
Caeli Malloy   +6 more
wiley   +1 more source

The influence of ultra‐processed foods on gut microbiome and inflammatory markers in schoolchildren from Northeastern Brazil

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective This study investigated the relationship between the consumption of ultra‐processed foods (UPF), dietary profile, and inflammation on the intestinal microbiome in children. Methods A cross‐sectional study was conducted using data from a community‐based controlled trial involving 82 children aged 7–11 years enrolled in public schools ...
Cristiane Cosmo Silva‐Luis   +3 more
wiley   +1 more source

Severe allergic reaction to ustekinumab reinitiation in a pediatric patient with Crohn's disease: A case report

open access: yesJPGN Reports, EarlyView.
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling   +2 more
wiley   +1 more source

Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Eosinophilic esophagitis (EoE) is a type 2 cytokine‐mediated chronic inflammatory condition leading to esophageal dysfunction. Dupilumab blocks IL‐4 and IL‐13 signaling, which are key inflammatory mediators in EoE and other allergic disorders.
Sindhura Kasturi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy